Drug Profile

Research programme: T-cell targeting exosome based therapeutics - Codiak Biosciences

Alternative Names: exoCD-3

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2023 No recent reports of development identified for research development in Autoimmune-disorders in USA
07 Jul 2019 Codiak Biosciences has patent No 201 902 028 92A1 pending covering exosomes for immuno-oncology and anti-inflammatory therapy in USA
13 Jun 2019 Codiak Biosciences has the patent No 201 901 755 06A1 pending, covering the methods of loading extracellular vesicles with payload molecules via homogenisation, in USA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com